260 related articles for article (PubMed ID: 35950315)
1. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy.
Dalo JD; Weisman ND; White CM
Ann Pharmacother; 2023 Apr; 57(4):489-502. PubMed ID: 35950315
[TBL] [Abstract][Full Text] [Related]
2. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.
Yacoub MS; El-Nakhal T; Hasabo EA; Shehata N; Wilson K; Ismail KH; Bakr MS; Mohsen M; Mohamed A; Abdelazim E; Ali HT; Soliman Z; Sayed A; Abdelsayed K; Caliskan K; Soliman O
Heart Fail Rev; 2024 Mar; 29(2):479-496. PubMed ID: 38112937
[TBL] [Abstract][Full Text] [Related]
4. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
Hegde SM; Lester SJ; Solomon SD; Michels M; Elliott PM; Nagueh SF; Choudhury L; Zemanek D; Zwas DR; Jacoby D; Wang A; Ho CY; Li W; Sehnert AJ; Olivotto I; Abraham TP
J Am Coll Cardiol; 2021 Dec; 78(25):2518-2532. PubMed ID: 34915982
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
Ho CY; Mealiffe ME; Bach RG; Bhattacharya M; Choudhury L; Edelberg JM; Hegde SM; Jacoby D; Lakdawala NK; Lester SJ; Ma Y; Marian AJ; Nagueh SF; Owens A; Rader F; Saberi S; Sehnert AJ; Sherrid MV; Solomon SD; Wang A; Wever-Pinzon O; Wong TC; Heitner SB
J Am Coll Cardiol; 2020 Jun; 75(21):2649-2660. PubMed ID: 32466879
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study.
Masri A; Lester SJ; Stendahl JC; Hegde SM; Sehnert AJ; Balaratnam G; Shah A; Fox S; Wang A
J Am Heart Assoc; 2024 Apr; 13(8):e030607. PubMed ID: 38591260
[TBL] [Abstract][Full Text] [Related]
7. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Wheeler MT; Jacoby D; Elliott PM; Saberi S; Hegde SM; Lakdawala NK; Myers J; Sehnert AJ; Edelberg JM; Li W; Olivotto I
Eur J Heart Fail; 2023 Feb; 25(2):260-270. PubMed ID: 36404399
[TBL] [Abstract][Full Text] [Related]
8. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
Cremer PC; Geske JB; Owens A; Jaber WA; Harb SC; Saberi S; Wang A; Sherrid M; Naidu SS; Schaff H; Smedira NG; Wang Q; Wolski K; Lampl KL; Sehnert AJ; Nissen SE; Desai MY
Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014986. PubMed ID: 36335645
[TBL] [Abstract][Full Text] [Related]
9. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Spertus JA; Fine JT; Elliott P; Ho CY; Olivotto I; Saberi S; Li W; Dolan C; Reaney M; Sehnert AJ; Jacoby D
Lancet; 2021 Jun; 397(10293):2467-2475. PubMed ID: 34004177
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.
Dong T; Nissen S; Ospina S; Desai MY
Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857
[TBL] [Abstract][Full Text] [Related]
11. Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.
Wang A; Spertus JA; Wojdyla DM; Abraham TP; Nilles EK; Owens AT; Saberi S; Cresci S; Sehnert A; Lakdawala NK
JACC Heart Fail; 2024 Mar; 12(3):567-579. PubMed ID: 37855754
[TBL] [Abstract][Full Text] [Related]
12. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy.
Chase Cole J; Benvie SF; DeLosSantos M
Clin Ther; 2024 Apr; 46(4):368-373. PubMed ID: 38508915
[TBL] [Abstract][Full Text] [Related]
13. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy.
Tower-Rader A; Ramchand J; Nissen SE; Desai MY
Expert Opin Investig Drugs; 2020 Nov; 29(11):1171-1178. PubMed ID: 32897741
[TBL] [Abstract][Full Text] [Related]
14. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
Desai MY; Owens A; Geske JB; Wolski K; Saberi S; Wang A; Sherrid M; Cremer PC; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Balasubramanyam A; Lampl K; Sehnert AJ; Nissen SE
Circulation; 2023 Mar; 147(11):850-863. PubMed ID: 36335531
[TBL] [Abstract][Full Text] [Related]
15. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.
Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP
Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641
[TBL] [Abstract][Full Text] [Related]
16. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
Cresci S; Bach RG; Saberi S; Owens AT; Spertus JA; Hegde SM; Lakdawala NK; Nilles EK; Wojdyla DM; Sehnert AJ; Wang A
Circulation; 2024 Feb; 149(7):498-509. PubMed ID: 37961906
[TBL] [Abstract][Full Text] [Related]
17. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.
Braunwald E; Saberi S; Abraham TP; Elliott PM; Olivotto I
Eur Heart J; 2023 Nov; 44(44):4622-4633. PubMed ID: 37804245
[TBL] [Abstract][Full Text] [Related]
18. Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy.
Pysz P; Rajtar-Salwa R; Smolka G; Olivotto I; Wojakowski W; Petkow-Dimitrow P
Kardiol Pol; 2021; 79(9):949-954. PubMed ID: 34268723
[TBL] [Abstract][Full Text] [Related]
19. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
[TBL] [Abstract][Full Text] [Related]
20. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE
Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
